INT56072

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1994
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 94
Total Number 94
Disease Relevance 53.16
Pain Relevance 28.19

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (NFKB1) mitochondrion (NFKB1) cytoplasm (NFKB1)
cytosol (NFKB1) signal transduction (NFKB1) nucleolus (NFKB1)
Anatomy Link Frequency
monocytes 2
RAW 264 2
stem cells 2
chondrocytes 1
MIA PaCa-2 1
NFKB1 (Homo sapiens)
Pain Link Frequency Relevance Heat
aspirin 55 100.00 Very High Very High Very High
cytokine 90 99.92 Very High Very High Very High
qutenza 26 99.92 Very High Very High Very High
Inflammatory response 12 99.92 Very High Very High Very High
cINOD 154 99.88 Very High Very High Very High
Inflammation 228 99.84 Very High Very High Very High
Chronic pancreatitis 21 99.70 Very High Very High Very High
antagonist 53 99.20 Very High Very High Very High
ketamine 44 99.20 Very High Very High Very High
Morphine 22 99.16 Very High Very High Very High
Disease Link Frequency Relevance Heat
Cancer 293 100.00 Very High Very High Very High
Necrosis 22 100.00 Very High Very High Very High
Repression 10 100.00 Very High Very High Very High
INFLAMMATION 311 99.84 Very High Very High Very High
Apoptosis 109 99.84 Very High Very High Very High
Acute Myeloid Leukemia 45 99.78 Very High Very High Very High
Pancreatitis 77 99.70 Very High Very High Very High
Disease 81 99.64 Very High Very High Very High
Pancreatic Cancer 36 99.52 Very High Very High Very High
Hypercalcemia 5 99.32 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Inhibition of the nuclear factor-kappaB (NF-kappaB) transcription factor family is one of the therapeutic strategies that are considered in AML.
Negative_regulation (Inhibition) of nuclear factor-kappaB associated with acute myeloid leukemia
1) Confidence 0.59 Published 2009 Journal Crit Rev Oncog Section Abstract Doc Link 20136626 Disease Relevance 0.66 Pain Relevance 0.10
Constitutive NF-kappaB activation has been detected in AML cells and NF-kappaB inhibition is therefore a possible therapeutic strategy in AML.
Negative_regulation (inhibition) of NF-kappaB associated with acute myeloid leukemia
2) Confidence 0.59 Published 2009 Journal Crit Rev Oncog Section Abstract Doc Link 20136626 Disease Relevance 0.93 Pain Relevance 0.08
Inhibition of the nuclear factor-kappaB (NF-kappaB) transcription factor family is one of the therapeutic strategies that are considered in AML.
Negative_regulation (Inhibition) of NF-kappaB associated with acute myeloid leukemia
3) Confidence 0.59 Published 2009 Journal Crit Rev Oncog Section Abstract Doc Link 20136626 Disease Relevance 0.66 Pain Relevance 0.10
It is therefore considered that the anti-cancer activities of NSAIDs (non-steroidal anti-inflammatory drugs) or glucocorticoids are probably partially related to the inhibition of NF-kappaB and new clinical trials are being initiated with old compounds such as sulfasalazine.
Negative_regulation (inhibition) of NF-kappaB associated with inflammation, cancer and cinod
4) Confidence 0.58 Published 2006 Journal Biochem. Pharmacol. Section Abstract Doc Link 16973133 Disease Relevance 0.59 Pain Relevance 0.20
Molecular studies demonstrated that ancient widely used drugs, known for their chemopreventive or therapeutic activities against human cancers, inhibit NF-kappaB, usually among other biological effects.
Negative_regulation (inhibit) of NF-kappaB associated with cancer
5) Confidence 0.58 Published 2006 Journal Biochem. Pharmacol. Section Abstract Doc Link 16973133 Disease Relevance 0.54 Pain Relevance 0.18
The activity of NF-kappaB was also decreased by combined-treatment with IL-1beta and 5-aminosalicylic acid.
Negative_regulation (decreased) of NF-kappaB
6) Confidence 0.58 Published 2009 Journal Dig Liver Dis Section Body Doc Link 18976971 Disease Relevance 0.15 Pain Relevance 0
Inhibition of NF-kappa B by sodium salicylate and aspirin.
Negative_regulation (Inhibition) of NF-kappa B associated with aspirin
7) Confidence 0.58 Published 1994 Journal Science Section Title Doc Link 8052854 Disease Relevance 0.36 Pain Relevance 0.32
These results were further confirmed by evaluating the drugs' ability to reduce nuclear NF-kappaB subunits, as well as the amount of phosphorylated IkappaBalpha in cytosolic fractions.
Negative_regulation (reduce) of NF-kappaB
8) Confidence 0.58 Published 2004 Journal Eur. J. Pharmacol. Section Abstract Doc Link 15464079 Disease Relevance 0.64 Pain Relevance 0.46
In conclusion, these results indicate that anti-inflammatory drugs differ largely in their ability to inhibit NF-kappaB activity and/or TNF-alpha release from human monocytes.
Negative_regulation (inhibit) of NF-kappaB in monocytes associated with inflammation and cinod
9) Confidence 0.58 Published 2004 Journal Eur. J. Pharmacol. Section Abstract Doc Link 15464079 Disease Relevance 0.62 Pain Relevance 0.45
Some of these agents (EGCG, genistein, and curcumin) appear to directly target specific RTKs, and all of these compounds cause inhibition of the activity of the transcription factors AP-1 and NF-kappaB, thus inhibiting cell proliferation and enhancing apoptosis.
Negative_regulation (inhibition) of NF-kappaB associated with apoptosis
10) Confidence 0.57 Published 2005 Journal Mutat. Res. Section Abstract Doc Link 15992833 Disease Relevance 0.40 Pain Relevance 0.13
As for mechanisms of action, KT-90 and morphine induced apoptosis, and inhibited tumor necrosis factor alpha (TNF-alpha) gene expression induced by tumor promoters, okadaic acid and 12-O-tetradecanoylphorbol-13-acetate, associated with reduction of NF-kappaB DNA binding activity.
Negative_regulation (reduction) of NF-kappaB associated with necrosis, cancer, apoptosis and morphine
11) Confidence 0.57 Published 1998 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 9837747 Disease Relevance 0.63 Pain Relevance 0.77
CONCLUSIONS: Our findings indicate the potential interest of TQ in the modulation of some immune and inflammatory responses probably by NF-kappaB inhibition.


Negative_regulation (inhibition) of NF-kappaB
12) Confidence 0.57 Published 2003 Journal Inflamm. Res. Section Body Doc Link 12835896 Disease Relevance 0.06 Pain Relevance 0
It is proposed that the major mechanism by these anti-inflammatory agents is a shared pathway dependent on the suppression of NF-kappaB activity, which may subsequently decrease transcription of growth factors, chemokines and proteases such as COX-2, VEGF, IL-8/CXCL8, MCP-1/CCL-2, MIP1alpha/CCL-3, tPA and uPA, which are shown to be elevated in ovarian carcinoma, and which play diverse roles such as inducing angiogenesis, invasion, autocrine growth loops and resistance to apoptosis.
Negative_regulation (suppression) of NF-kappaB associated with chemokine, inflammation, ovarian cancer and apoptosis
13) Confidence 0.57 Published 2004 Journal Neoplasma Section Abstract Doc Link 15254653 Disease Relevance 0.91 Pain Relevance 0.71
These observations imply that anti-inflammatory agents that suppress NF-kappaB or NF-kappaB-regulated products should have a potential in both the prevention and treatment of cancer.
Negative_regulation (suppress) of NF-kappaB associated with inflammation and cancer
14) Confidence 0.57 Published 2006 Journal Biochem. Pharmacol. Section Abstract Doc Link 16889756 Disease Relevance 2.15 Pain Relevance 0.36
The molecular mode of action of HDAC inhibitors is still controversial but seems to rely on reduced inflammatory mediator production, such as nitric oxide or cytokines, which implies inhibition of the transcription factor NF-kappaB.
Negative_regulation (inhibition) of NF-kappaB associated with inflammation and cytokine
15) Confidence 0.57 Published 2005 Journal Drug Discov. Today Section Abstract Doc Link 15708534 Disease Relevance 0.70 Pain Relevance 0.32
Inhibition of NF-kappaB and/or TNFalpha is a putative mechanism for thalidomide efficacy in AS.
Negative_regulation (Inhibition) of NF-kappaB associated with spinal inflammation
16) Confidence 0.57 Published 2002 Journal Clin. Exp. Rheumatol. Section Abstract Doc Link 12463469 Disease Relevance 0.45 Pain Relevance 0.41
Broad spectrum anti-inflammatory drugs may be more effective, and include inhibitors of PDE4, p38 MAPK and NF-kappaB, but side effects will be a major limitation so that inhaled delivery will be necessary.
Negative_regulation (inhibitors) of NF-kappaB associated with inflammation and cinod
17) Confidence 0.57 Published 2008 Journal Curr Opin Pharmacol Section Abstract Doc Link 18457992 Disease Relevance 0.52 Pain Relevance 0.40
This gene encodes VCP, which has a role in targeting the inhibitor of NFkappaB for degradation by the proteasome.
Negative_regulation (inhibitor) of NFkappaB
18) Confidence 0.57 Published 2006 Journal Nature clinical practice. Rheumatology Section Abstract Doc Link 16932700 Disease Relevance 1.46 Pain Relevance 0.05
Propofol also reduced the LPS-enhanced iNOS mRNA and NF-kappaB protein levels whilst it increased eNOS mRNA expression (P < 0.05).
Negative_regulation (reduced) of NF-kappaB
19) Confidence 0.56 Published 2006 Journal Inflamm. Res. Section Body Doc Link 17122960 Disease Relevance 0 Pain Relevance 0
Recent studies on the apoptotic potential of arsenic trioxide have elucidated some of its causal mechanisms, including elevation of intracellular H2O2, inhibition of NF-kappaB activity, and inhibition of GTP-induced polymerization of tubulin.
Negative_regulation (inhibition) of NF-kappaB associated with apoptosis
20) Confidence 0.56 Published 2004 Journal J. Exp. Clin. Cancer Res. Section Abstract Doc Link 15354410 Disease Relevance 0.50 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox